2021
Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis
Sandborn WJ, Feagan BG, D'Haens G, Wolf DC, Jovanovic I, Hanauer SB, Ghosh S, Petersen A, Hua SY, Lee JH, Charles L, Chitkara D, Usiskin K, Colombel JF, Laine L, Danese S. Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. New England Journal Of Medicine 2021, 385: 1280-1291. PMID: 34587385, DOI: 10.1056/nejmoa2033617.Peer-Reviewed Original ResearchConceptsActive ulcerative colitisMaintenance therapyUlcerative colitisClinical remissionEnd pointClinical responseCohort 2Cohort 1Selective sphingosine-1-phosphate receptor modulatorSphingosine-1-phosphate receptor modulatorsElevated liver aminotransferase levelsKey secondary end pointLiver aminotransferase levelsPlacebo-controlled trialPrimary end pointSecondary end pointsPercentage of patientsDouble-blind mannerInflammatory bowel diseaseSame daily doseIncidence of infectionHistologic end pointsMayo scoreUnderwent randomizationAminotransferase levels
2010
Cytomegalovirus Infection in Patients with Active Inflammatory Bowel Disease
Kim JJ, Simpson N, Klipfel N, DeBose R, Barr N, Laine L. Cytomegalovirus Infection in Patients with Active Inflammatory Bowel Disease. Digestive Diseases And Sciences 2010, 55: 1059-1065. PMID: 20112061, DOI: 10.1007/s10620-010-1126-4.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseActive inflammatory bowel diseaseActive ulcerative colitisUC patientsIndex flareCMV infectionUlcerative colitisCrohn's diseaseCytomegalovirus infectionBowel diseasePrevalence of CMVCourse of diseaseAcute exacerbationIBD colitisUC flareCMV antigensConclusionsThe prevalenceIndex endoscopyMethodsConsecutive patientsClinical courseSevere morbidityClinical featuresImmunohistochemistry stainingGeneral populationPatients